Navigation Links
Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies

New research continues to reinforce the efficacy of RESPeRATE while

highlighting interest in the device by the scientific community

BERLIN and NEW YORK, June 16 /PRNewswire/ -- European Society of Hypertension -- Booth # 21, Hall 15.1 -- InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced the findings of new studies and analysis highlighting RESPeRATE -- the only medical device cleared by the FDA and CE-approved for the treatment of hypertension. Five posters will be presented at the European Society of Hypertension meeting (ESH) in Berlin beginning June 14, 2008. Two of the five posters focus on RESPeRATE's effect on blood pressure as measured by 24-hour ambulatory blood pressure monitoring. Three of the posters also present new findings in the emerging field of obtaining vascular risk parameters from blood pressure measurements. The fifth poster demonstrates the benefits of RESPeRATE in patients with chronic heart failure.

"InterCure is making great strides within the European marketplace and has received a tremendous response from both the scientific and consumer communities," says Erez Gavish, president and CEO of InterCure. "The continued clinical interest is producing a constant drumbeat of validation for RESPeRATE, paving the path for the successful charge into retail outlets in Europe and the U.S. and building on the more than 100,000 hypertension sufferers who have already adopted RESPeRATE as a treatment for their hypertension."

Results of the findings related to RESPeRATE are being presented as posters at ESH and are as follows:

-- PS26/WED/05 -- A study performed in Turkey, led by Prof. Erdine,

Department of Cardiology, Istanbul University, demonstrated that the

RESPeRATE device provides daytime and nighttime blood pressure

reductions as measured by 24-hour ambulatory monitoring. The study

also demonstrated that patients were compliant with the device and that

no adverse side effects were reported.

-- PS33/THU/01 -- Pooled results from two separate studies led by Profs.

Rosenthal and the Erdine study (above), utilizing 24-hour ambulatory

blood pressure monitoring demonstrated that RESPeRATE benefits

uncontrolled-hypertension sufferers. The analysis demonstrated a

clinically significant blood pressure reduction throughout both daytime

and nighttime. RESPeRATE was also found to independently reduce high

values of a risk-associated arterial property (S-D slope/AASI) derived

from the relationship between systolic and diastolic pressures.

-- PS34/MON/08 -- Data analysis led by Dr. Benjamin Gavish, chief

scientific officer, InterCure, Ltd., of a study performed in Italy,

conducted by Prof. Gianfranco Parati, explored, for the first time, the

linear relationships between systolic and diastolic blood pressure from

beat-to-beat measurements. The derived risk-related parameters (S-D

slope and AASI) are acutely influenced by breathing patterns and neck


-- PS34/MON/18 -- An Israeli study, conducted by Dr. Iddo Ben-Dov and

Prof. Michael Burzstyn from Hadassah Medical Center, and Dr. Benjamin

Gavish, concluded that the ratio of systolic to diastolic blood

pressure variability is shown to be a blood pressure-independent

predictor of mortality, associated with the linear relationship between

systolic and diastolic pressures.

-- PS18/WED/58 -- An Italian, randomized controlled study, led by Prof. G.

Parati from the University of Milan-Bicocca concluded that device-

guided paced breathing at home is feasible and improves prognostically

relevant clinical and instrumental parameters in heart failure

patients. It is recommended as an additional long-term treatment

program for these patients.

About InterCure Ltd. and RESPeRATE

InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE(R) ( In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective non-drug therapy with no side effects.

RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device's efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.

With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world's most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.

InterCure has an exciting product pipeline based on its broadly-patented "Device-Guided Breathing" technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.

Forward-Looking Statements

This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward- looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


Lisa Mokaba Brian Packard

Schwartz Communications InterCure, Inc.

+1-781-684-0770 +1-646-652-5800 x.7134

SOURCE InterCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
4. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
5. Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADAs Recommended Target for Blood Sugar Control
6. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
7. Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
8. New Study Linking High Normal Blood Pressure to Significant Cardiovascular Risk
9. Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
10. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... Cardiac Pacemaker Market Outlook to 2019 - Rise in Cardiac ... " report to their offering. ... Boston scientific and others. --> ... Medtronic, Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
Breaking Medicine Technology:
(Date:11/27/2015)... Francisco, California (PRWEB) , ... November 27, 2015 , ... ... Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's ... at the Canterbury House at the University of Michigan in Ann Arbor. The According ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... substance abuse located in central Michigan, have come together on Thanksgiving Day to ... produced video, available for viewing on the Serenity Point YouTube channel, patients displayed ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record ... performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the ... to rebuild lives and it’s an honor to have served all of these women.” ...
Breaking Medicine News(10 mins):